Sim Eun Ah, Kim Seon-Young, Kim SangNam, Mun Eun-Gyung
Jeonju AgroBio-Materials Institute (JAMI), Jeonju-si 54810, Republic of Korea.
Microorganisms. 2024 Dec 27;13(1):32. doi: 10.3390/microorganisms13010032.
This study evaluated the probiotic potential of lactic acid bacteria (LAB) isolated from fermented milk and soymilk products purchased from local markets. The LAB strains were assessed for acid and bile resistance, antibiotic resistance, and adhesion to human intestinal epithelial models. (JAMI_LB_02) and (JAMI_LB_05) showed the highest survival rates in artificial gastric and bile juices, at 87.17 ± 0.02% and 96.71 ± 4.10%, respectively, with all strains (except JAMI_LB_03) demonstrating antibiotic resistance. Adhesion ability indicated the superior performance of JAMI_LB_02 and JAMI_LB_05 compared to standard strains. JAMI_LB_02 adhered to Caco-2 cells at 2.10 ± 0.94% and to HT-29 cells at 3.32 ± 0.38%, exceeding standard strains (1.06 ± 0.13% and 1.89 ± 0.58%). JAMI_LB_05 achieved the highest rates at 5.62 ± 1.33% on Caco-2 and 5.76 ± 0.46% on HT-29 cells. Their combination (JAMI_LB_02 + JAMI_LB_05) significantly enhanced adhesion to 18.57 ± 5.49% on Caco-2 and 21.67 ± 8.19% on HT-29 cells, demonstrating strong synergy. These findings highlight the probiotic potential of the isolated LAB strains, particularly in mixed formulations, which may improve intestinal survival, adaptability, and efficacy. Further in vivo studies are warranted to validate their clinical applications and optimize strain combinations for human health benefits.
本研究评估了从当地市场购买的发酵乳和豆浆产品中分离出的乳酸菌(LAB)的益生菌潜力。对LAB菌株进行了耐酸和耐胆汁性、抗生素抗性以及对人肠道上皮模型的粘附性评估。(JAMI_LB_02)和(JAMI_LB_05)在人工胃液和胆汁中显示出最高的存活率,分别为87.17±0.02%和96.71±4.10%,所有菌株(JAMI_LB_03除外)均表现出抗生素抗性。粘附能力表明JAMI_LB_02和JAMI_LB_05与标准菌株相比具有更优的性能。JAMI_LB_02对Caco-2细胞的粘附率为2.10±0.94%,对HT-29细胞的粘附率为3.32±0.38%,超过了标准菌株(1.06±0.13%和1.89±0.58%)。JAMI_LB_05在Caco-2细胞上的粘附率最高,为5.62±1.33%,在HT-29细胞上为5.76±0.46%。它们的组合(JAMI_LB_02 + JAMI_LB_05)显著增强了对Caco-2细胞的粘附率,达到18.57±5.49%,对HT-29细胞的粘附率达到21.67±8.19%,显示出强大的协同作用。这些发现突出了分离出的LAB菌株的益生菌潜力,特别是在混合制剂中,这可能会提高肠道存活率、适应性和功效。有必要进行进一步的体内研究,以验证它们的临床应用,并优化菌株组合以实现对人类健康的益处。